Difference between revisions of "Avelumab (Bavencio)"
m (Text replacement - "[[Media:" to "[[File:") |
m (Text replacement - "[[File:" to "[[:File:") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.<ref name=insert>[https://www.bavencio.com/en_US/document/Prescribing-Information.pdf Avelumab (Bavencio) package insert]</ref><ref>[[File:Avelumab.pdf | Avelumab (Bavencio) package insert (locally hosted backup)]]</ref><ref>[http://www.bavencio.com Bavencio manufacturer's website]</ref> | + | Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.<ref name=insert>[https://www.bavencio.com/en_US/document/Prescribing-Information.pdf Avelumab (Bavencio) package insert]</ref><ref>[[:File:Avelumab.pdf | Avelumab (Bavencio) package insert (locally hosted backup)]]</ref><ref>[http://www.bavencio.com Bavencio manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 04:06, 20 September 2021
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
Bladder cancer
- 5/9/2017: Granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. (New disease entity; based on JAVELIN)
- 6/30/2020: Approved for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. (Converted to regular approval; expanded to maintenance setting; based on JAVELIN Bladder 100)
Merkel cell carcinoma
- 3/23/2017: Approved for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma (MCC). (Initial approval; based on JAVELIN Merkel 200)
Renal cell carcinoma
- 5/14/2019: Approved in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (New disease entity; based on JAVELIN Renal 101)
Also known as
- Code name: MSB0010718C
- Brand name: Bavencio